Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 4/2005

01.04.2005 | Review Article

HIV-Associated Neuropathic Pain

Epidemiology, Pathophysiology and Management

verfasst von: Susama Verma, Lydia Estanislao, Dr David Simpson

Erschienen in: CNS Drugs | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Peripheral neuropathy is associated with numerous systemic illnesses including HIV infection. Neuropathic pain constitutes approximately 25–50% of all pain clinic visits. Distal symmetrical polyneuropathy (DSP) is the most common form of peripheral neuropathy in individuals with HIV infection. DSP is distinguished from other forms of neuropathy on the basis of history and neurological examination. The pain associated with DSP can be debilitating. Therefore, it is important to diagnose HIV-associated DSP properly and treat the neuropathic pain in order to improve quality of life. We review the clinical manifestations, epidemiology, pathophysiology and management strategies for HIV-associated DSP.
Literatur
1.
2.
Estanislao L, Carter K, McArthur J, et al. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004 Dec; 37(5): 1584–6PubMedCrossRef
3.
Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002 Jun 25; 58(12): 1764–8PubMedCrossRef
4.
Simpson DM. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002; 8 (2) Suppl. 1: 33–41CrossRef
5.
Newshan G. Pain in human immunodeficiency virus disease. Semin Oncol Nurs 1997 Feb; 13(1): 36–41PubMedCrossRef
6.
Breitbart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain 1996 May–Jun; 65(2–3): 243–9PubMedCrossRef
7.
Verma S, Estanislao L, Mintz L, et al. Controlling neuropathic pain in HIV. Curr Infec Dis Rep 2004; 6: 237–42CrossRef
8.
National Institute of Allergy and Infectious Disease. HIV/AIDS Statistics. January 2004. National Institutes of Health. Bethesda (MD): US Department of Health and Human Services Public Health Service, 2004
9.
Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002 Dec; 8 Suppl. 2: 115–21CrossRef
10.
Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003, 77
11.
Wang C, Vlahov D, Galai N. et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004 Sep 15; 190(6): 1046–1054. Epub 2004 Aug 17PubMedCrossRef
12.
Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002 Dec; 8 Suppl. 2: 115–21CrossRef
13.
Williams D, Geraci A, Simpson DM. AIDS and AIDS-treatment neuropathies. Curr Neurol Neurosci Rep 2001 Nov; 1(6): 533–8PubMedCrossRef
14.
So YT, Holtzman DM, Abrams DI, et al. Peripheral neuropathy associated with acquired immunodeficiency syndrome: prevalence and clinical features from a population-based survey. Arch Neurol 1988 Sep; 45(9): 945–8PubMedCrossRef
15.
Geraci A, Simpson D. Neurological manifestations of HIV-1 infection in the HAART era. Compr Ther 2001; 27: 232–41PubMedCrossRef
16.
Childs EA, Lyles RH, Seines OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607–13PubMedCrossRef
17.
Simpson DM, Tagliati N. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retroviral 1995; 9: 153–61
18.
Martin C, Solders G, Göran MD, et al. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000; 54(11): 2120–7PubMedCrossRef
19.
Morgello S, Estanislao L, Simpson D, et al., on behalf of the Manhattan HIV Brain Bank. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 4: 546–51CrossRef
20.
Schifitto G, McDermott MP, McArthur JC. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58(12): 1764–8PubMedCrossRef
21.
Savasta AM. HIV: associated transmission risks in older adults. An integrative review of the literature. J Assoc Nurses AIDS Care 2004; 15(1): 50–9CrossRef
22.
Lopez OL, Becker JT, Dew MA, et al. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur J Neurol 2004; 11(2): 97–102PubMedCrossRef
23.
Kieburtz KD, Giang DW, Schiffer RB, et al. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection: association with neurological dysfunction. Arch Neurol 1991 Mar; 48(3): 195–207CrossRef
24.
Verucchi G, Calza L, Manfredi R, et al. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004; 32(1): 33–46PubMedCrossRef
25.
Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with Hepatitis C virus infection: a prospective multicenter study of 321 patients. Medicine 2000; 79: 47–56PubMedCrossRef
26.
Cherry CL, McArthur JC, Hoy JF, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003 Feb; 26(2): 195–207PubMedCrossRef
27.
Biehl J, Skavlem J. Toxicity of isoniazid. Am Rev Tuberc 1953; 68: 296–7PubMed
28.
Gammon GD, Burge FW, King G. Neural toxicity in patients treated with isoniazid. AMA Arch Neurol Psychiatry 1953; 70: 64–9PubMedCrossRef
29.
Jones W, Jones G. Peripheral neuropathy due to isoniazid: report of two cases. Lancet 1953; I: 1073–4CrossRef
30.
Berger A, Schaumburg H, Schroeder C, et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992; 42: 1367–70PubMedCrossRef
31.
Tugwell P, James S. Peripheral neuropathy with ethambutol. Postgrad Med J 1972; 48(565): 667–70PubMedCrossRef
32.
33.
Dreger L, Gleason P, Chowdhry T, et al. Intermittent-dose metronidazole-induced peripheral neuropathy. Ann Pharmacother 1998; 32: 267–8PubMedCrossRef
34.
Sahenk S, Brady S, Mendell J. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 1987; 10: 80–4PubMedCrossRef
35.
Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003; 2: 342–95CrossRef
36.
Fullerton P, O’Sullivan D. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968; 31: 543–51PubMedCrossRef
37.
38.
DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001; 90: 1–6PubMedCrossRef
39.
Sorkin LS, Puig S, Jones DL. Spinal bicuculline produces hypersensitivity of dorsal horn neurons: effects of excitatory amino acid antagonists. Pain 1998 Aug; 77(2): 181–90PubMedCrossRef
40.
Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000 Jun; 101(6): 359–71PubMedCrossRef
41.
Baba H, Ji RR, Kohno T, et al. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci 2003 Nov; 24(3): 818–30PubMedCrossRef
42.
Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001; 6: 21–7PubMedCrossRef
43.
Apostolski S, McAlarney T, Quattrini A, et al. The gp120 glycoprotein of human immunodeficiency virus type 1 binds to sensory ganglian neurons. Ann Neurol 1993 Dec; 34(6): 855–63PubMedCrossRef
44.
Herzberg U, Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J Neuroimmunol 2001; 116: 29–39PubMedCrossRef
45.
Oh SB, Tran PB, Gillard SE, et al. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001; 21(14): 5027–35PubMed
46.
Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003 Nov; 60(11): 1524–34PubMedCrossRef
47.
Verma S, Micsa E, Estanislao L. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep 2004; 4: 62–7PubMedCrossRef
48.
Breen EC. Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 2002; 3: 295–304CrossRef
49.
Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences. The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci 2002; 1: 19–32
50.
Nagano I, Shapshak P, Yoshioka M, et al. Increased NADPH-diaphrose reactivity and cytokine expression in dorsal root ganglia in acquired immunodeficiency syndrome. J Neuro Sci 1996 Mar; 136(1–2): 117–28CrossRef
51.
Yoshioka M, Shapshak P, Srivastava AK, et al. Expression of HIV-1 and interleukin-6 in lumbosacral dorsal root ganglia of patients with AIDS. Neurology 1994 Jun; 44(6): 1120–30PubMedCrossRef
52.
Scaravilli F, Sinclair E, Arango JC, et al. The pathology of the posterior root ganglia in AIDS and its relationship to the pallor of the gracile tract. Acta Neuropathol (Berl) 1992; 84(2): 163–70CrossRef
53.
Moyle GJ. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911–36PubMedCrossRef
54.
55.
Cherry CL, McArthur JC, Hoy JF, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003; 26(2): 195–207PubMedCrossRef
56.
Dalakas M, Semino-Mora C, Leon-Monzon M, et al. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001; 81(11): 1537–44PubMedCrossRef
57.
McKay Hart A, Wiberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L-carnitine treatment. Neurosci Lett 2002 Dec 16; 334(3): 181–5PubMedCrossRef
58.
Colucci WJ, Gandour RD. Carnitine acetyltransferase: a review of its biology, enzymology and bioorganic chemistry. Bioorg Chem 1988; 16: 307–34CrossRef
59.
Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogs. AIDS 1997; 11: 185–90PubMedCrossRef
60.
Simpson DM, Katzenstein D, Haidich B, et al. Plasma carnitine in HIV-associated neuropathy. AIDS 2001; 15(16): 2207–8PubMedCrossRef
61.
Verma S, Micsa E, Estanislao L, et al. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep 2004; 1: 62–7CrossRef
62.
Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38(5): 794–6PubMedCrossRef
63.
Watters MR, Poff PW, Shiramizu BT, et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004 Apr 27; 62(8): 1378–83PubMedCrossRef
64.
Verma A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 2001 Mar; 6(1): 8–13PubMedCrossRef
65.
Kieburtz K, Seidlin M, Lambert J. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J AIDS 1992; 5: 60–4
66.
Breitbart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain 1996 May–Jun; 65(2–3): 243–9PubMedCrossRef
67.
Breitbart W, Kairn M, Rosenfeld B. Clinicians’ perceptions of barriers to pain management in AIDS. J Pain Symptom Manage 1999 Sep; 18(3): 203–11PubMedCrossRef
68.
Breitbart W, Passik S, McDonald MV, et al. Patient-related barriers to pain management in ambulatory AIDS patients. Pain 1998 May; 76(1–2): 9–16PubMedCrossRef
69.
Haythornthwaite JA, Benrud-Larson LM. Psychological assessment and treatment of patients with neuropathic pain. Curr Pain Headache Rep 2001; 5(2): 124–9PubMedCrossRef
70.
Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004 Jun; 17(3): 163–8PubMed
71.
Chavez C. Prickly business: the finer points of acupuncture. Posit Aware 1995 Jan–Feb; 14-5
72.
Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA 1998; 280: 1590–5PubMedCrossRef
73.
Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51(6): 1682–8
74.
Simpson D, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000; 54: 2115–9PubMedCrossRef
75.
Simpson DM, McArthur JC, Olney R, et al. Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003 May 13; 60(9): 1508–14
76.
Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg 2004 Jul–Aug; 12(4): 221–33
77.
Backonja M, Malan P, Brady S, et al. One-hour high-concentration trans-capsaicin applications provide durable pain relief in initial and repeat treatment of postherpetic neuralgia (PHN) [abstract no. S51.002]. American Academy of Neurology 56th Annual Meeting; 2004 Apr 24–May 1; San Francisco
78.
Simpson D, Brown S, Sampson J, et al. A single application of high concentration trans-capsaicin leads to 12 weeks of pain relief in HIV DSP: results of an open label trial [presentation]. American Academy of Neurology 56th Annual Meeting; 2004 Apr 24–May 1; San Francisco
79.
Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 169–74PubMedCrossRef
80.
Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology 1998; 51: 1682–8PubMedCrossRef
81.
Simpson DM. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002 Dec; 8 Suppl. 2: 33–41CrossRef
82.
Kolson DL, Gonzalez-Scarano F. HIV-associated neuropathies: role of HIV-1, CMV, and other viruses. J Peripher Nerv Syste 2001 Mar; 6(1): 2–7CrossRef
83.
Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000 Jun; 59(6): 1251–60PubMedCrossRef
84.
Gozlan J, Amrani M, Baudrimont M, et al. A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. AIDS 1995 Mar; 9(3): 253–60PubMed
85.
Gozlan J, Salord JM, Roullet E, et al. Rapid detection of cytomegalovirus. J Infect Dis 1992 Dec; 166(6): 1416–21PubMedCrossRef
86.
Cornford ME, Ho HW, Vinters HV. Correlation of neuromuscular pathology in acquired immune deficency syndrome patients with cytomegalovirus infection and zidovudine treatment. Acta Neuropathol (Berl) 1992; 84(5): 516–29CrossRef
87.
Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999; 53: 1641–7PubMedCrossRef
88.
Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998 Sep; 21(3): 531–43PubMedCrossRef
89.
Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999 May; 81(1–2): 135–45PubMedCrossRef
90.
McArthur JC, Tiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54(5): 1080–8
91.
Simpson D, Dorfman D, Olney R, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 1996; 47: 1254–9
92.
Campana WM, Eskeland N, Calcutt NA, et al. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 1998 Apr; 19(2): 237–44PubMed
93.
Yan L, Otero DA, Hiraiwa M, et al. Prosaptide D5 reverses hyperalgesia: inhibition rat. Neurosci Lett 2000 Jan; 278(1–2): 120–2PubMedCrossRef
94.
Editorial. New advances promising in treating neuropathy: experts explain what’s the latest and best. AIDS Alert 2004 Mar; 19(3): 31–3
Metadaten
Titel
HIV-Associated Neuropathic Pain
Epidemiology, Pathophysiology and Management
verfasst von
Susama Verma
Lydia Estanislao
Dr David Simpson
Publikationsdatum
01.04.2005
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 4/2005
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200519040-00005

Weitere Artikel der Ausgabe 4/2005

CNS Drugs 4/2005 Zur Ausgabe

Review Article

Social Functioning

Adis Drug Profile

Intranasal Sumatriptan in Adolescents with Migraine

Adis Drug Profile

Intranasal Sumatriptan in Adolescents with Migraine

Adis Drug Profile

Intranasal Sumatriptan

Review Article

Psychological Symptoms Associated with Genital Herpes Virus Infections

Leading Article

Substance P Receptor Antagonists in Psychiatry

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise